Journals / Yeni Tıp Dergisi / 2014 / Cilt: 31 - Sayı: 3

Investigation of the (DDAH1) T87M mutation of dimethylarginine dimethylaminohydrolase (DDAH E.C. 3.5.3.18) (DDAH 1) enzyme and the levels of asymmetric dimethylarginine (ADMA) in patients with coronary heart disease

Koroner kalp hastalarında asimetrik dimetil arjinin düzeyleri ve dimetilarjinin dimetilamino hidrolaz enziminin genetic polimorfizmi

Pages
192–197
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Polymorphism studies with wider population and detailed investigation of risk factors in these polymorphic subjects will contribute to ensure the role of high ADMA levels in cardiovascular diseases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Genetic polymorphism may enhance the predisposition to cardiovascular events in patients with coronary heart disease (CHD).
📊
Key Findings & Data:The aim of this study is to contribute further treatment protocol development via investigation serum ADMA levels and dimethylarginine dimethylaminohydrolase DDAH 1 (E.C. 3.5.3.18) T87M mutation of CHD patients.
💡
Conclusion & Impact:Conclusions: Polymorphism studies with wider population and detailed investigation of risk factors in these polymorphic subjects will contribute to ensure the role of high ADMA levels in cardiovascular diseases.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Genetic polymorphism may enhance the predisposition to cardiovascular events in patients with coronary heart disease (CHD). The aim of this study is to contribute further treatment protocol development via investigation serum ADMA levels and dimethylarginine dimethylaminohydrolase DDAH 1 (E.C. 3.5.3.18) T87M mutation of CHD patients. Material and Methods: 50 CHD patients and 50 healthy volunteers from Konya region were included to this study. Serum ADMA levels were analyzed by high performance liquid chromatograpy. DDAH (E.C. 3.5.3.18) T87M mutation were determined by PCR from extracted whole blood DNA samples. Results: ADMA levels were significantly higher in patient group compared to control group and there was no statistically diffference between groups for Arginine / ADMA ratio (p<0.001, p=0.08 respectively). Triglyceride levels were significantly higher in patient group compared to control group (p=0.033) and HDL- cholesterol levels were significantly lower in patient group compared to control group (p<0.001). In DDAH 1 T87M polymorphism gene analysis, there was only one heterozygote patient, the other participiants were wildtype. Conclusions: Polymorphism studies with wider population and detailed investigation of risk factors in these polymorphic subjects will contribute to ensure the role of high ADMA levels in cardiovascular diseases.

Özet

Amaç: Koroner kalp hastal ı ğ ı olan bireylerde genetik olarak polimorfizm olmas ı kardiyovasküler olaylara yatk ı nl ı ğ ı arttı rabilir. Dimetilarjinin Dimetilamino Hidrolaz (DDAH) enziminde bu genetik de ğ iş imin saptanmas ı ile bu hastal ı k grubunda daha ileri tedavi protokolleri geliştirilmesine katk ı sa ğ lamak için koroner kalp hastalar ı nda Asimetrik Dimetil Arjinin (ADMA) seviyeleri ve DDAH 1 (E.C. 3.5.3.18) enziminin T87M mutasyonu incelendi. Materyal ve Metot: Konya bölgesinde ya şayan 50 koroner kalp hastası ve 50 kontrol bireyi çal ı şmaya dahil edilmiştir. Serum örneklerinden ADMA yüksek performansl ı s ı vı kromatografisi, tam kan örneklerinden izole edilen DNA örneklerinden DDAH 1 T87M mutasyonu PCR yöntemi ile çal ı şı ld ı . Bulgular: ADMA düzeyleri hasta grubunda kontrol grubuna k ı yasla anlaml ı olarak yüksek bulunmu ş olup Arjinin/ADMA oranlar ı nda istatistiksel olarak bir farkl ı l ı k gözlenmemiş tir (Sı ras ı yla p<0,001 ve p=0.08). Hasta grubunda trigliserid düzeyleri kontrol grubuna k ı yasla anlaml ı olarak yüksek (p=0,033), Yüksek yo ğ unluklu lipoprotein (HDL)-kolesterol seviyeleri ise dü ş ük tespit edilmiştir (p<0,001). Hasta grubundan bir kiş ide DDAH 1 T87M gen polimorfizmi “heterozigot” bulunurken “homozigot” varyant hiçbir kat ı l ı mcı da gözlenmemiştir. Diğ er katı l ı mcı larda genin ilgili bölgesi “wild tip” olarak belirlenmiştir. Sonuçlar: Daha geniş bir toplum kesimi ile yapı lacak polimorfizm çal ı ş malar ı ve bu polimorfik bireylerde risk etmenlerinin detayl ı olarak incelenmesi yüksek ADMA düzeylerinin kardiyovasküler olaylardaki rolünü netle ş tirilmesi ad ı na katk ı sa ğ layacaktı r.

🔖

Cite This Article

ABUŞOĞLU, S., ÜNLÜ, A., ÇELİK, H. T., TANER, A., KAYRAK, M., ÖÇ, M. A. H. (2014). Investigation of the (DDAH1) T87M mutation of dimethylarginine dimethylaminohydrolase (DDAH E.C. 3.5.3.18) (DDAH 1) enzyme and the levels of asymmetric dimethylarginine (ADMA) in patients with coronary heart disease. Yeni Tıp Dergisi, Cilt: 31 - Sayı: 3, 192–197. https://ajindex.com/articles/338386

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Murray CJ, Lopez AD. Global mortality disability and the contribution of risk factors: Global Burden of Disease study. Lancet 1997;349:36-42
  2. Ross R. The pathogenesis of atherosclerosis. NEJM 1986;314:488-512
  3. Tousoulis D, Davies G, Stefanadis C, Toutouzas P, Ambrose JA. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003;89:93-7
  4. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the centers for disease control and prevention and the american heart association. Circulation 2003;107:499–511
  5. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl 2003; 4:33–40
  6. Weidinger FF, McLenachan JM, Cybulsky MI, et al. Persistent dysfunction of regenerated endothelium following balloon angioplasty of rabbit iliac artery. Circulation 1990;81:1667–79
  7. Masuda H, Goto M, Tamaoki S, Azuma H. Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxaninduced hyperglycaemia. Br J Pharmacol 1999;126:211–8
  8. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99: 1141–6
  9. McDermott JR. Studies on the catabolism of NG-methylarginine, NG, N_G dimethylarginine and NG,NG-dimethylarginine. Biochem J 1976;154: 179–84
  10. Murray-Rust J, Leiper J, McAlister M, et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol. 2001;8:679–83
  11. Pankaj S, Paul B. Candidate Gene-Based Studies Still Have Value in A World Dominated By Whole Genome Approaches. Circ Res 2010;106:1019- 21
  12. Hasegawa K, Wakino S, Tatematsu S, et al. Role Of Asymmetric Dimethylarginine İn Vascular Injury İn Transgenic Mice Overexpressing Dimethylarginie Dimethylaminohydrolase 2. Circulation Research 2007; 101:2-10
  13. Chen BM, Xia LW, Zhao RQ. Determination ofNG,NG dimethylarginine in human plasma by highperformanceliquid chromatography. J Chromatogr B 1997;692:467-71
  14. Stühlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocysteinemia: Role of ADMA. Circulation 2003;108:933–8
  15. Leiper JM, Santa Maria J, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology to micr